Acuta Capital Partners, LLC Brainstorm Cell Therapeutics Inc. Transaction History
Acuta Capital Partners, LLC
- $70.3 Million
- Q4 2024
A detailed history of Acuta Capital Partners, LLC transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 2,500 shares of BCLI stock, worth $4,325. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,500Holding current value
$4,325% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BCLI
# of Institutions
9Shares Held
549KCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY386KShares$668,4960.0% of portfolio
-
Raymond James & Associates St Petersburg, FL95.2KShares$164,6140.0% of portfolio
-
Liberty Wealth Management LLC Oakland, CA22.7KShares$39,2120.01% of portfolio
-
Weaver Consulting Group15.6KShares$27,0270.01% of portfolio
-
S.C. Financial Services, Inc.12.7KShares$21,9460.03% of portfolio
About BRAINSTORM CELL THERAPEUTICS INC.
- Ticker BCLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,486,200
- Market Cap $63.1M
- Description
- Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...